BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tanezumab: Phase II data

In a double-blind Phase II (Study 1010) trial in 51 patients, 200 µg/kg IV tanezumab produced a clinically significant reduction in average daily pain score vs. placebo at week 6. Pfizer said statistical significance was not formally...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >